Ovid Therapeutics (NASDAQ:OVID – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.
Several other research firms have also recently issued reports on OVID. Oppenheimer upped their price objective on Ovid Therapeutics from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Monday, August 3rd. Cantor Fitzgerald initiated coverage on Ovid Therapeutics in a report on Friday, October 9th. They issued an “overweight” rating on the stock. HC Wainwright raised their target price on Ovid Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Roth Capital reissued a “buy” rating and set a $8.00 target price on shares of Ovid Therapeutics in a research report on Thursday, September 3rd. Finally, B. Riley Financial restated a “buy” rating on shares of Ovid Therapeutics in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Ovid Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $6.00.
Get Our Latest Analysis on OVID
Ovid Therapeutics Stock Performance
Shares of OVID stock opened at $2.54 on Friday. The company has a current ratio of 11.97, a quick ratio of 11.97 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average price of $2.51 and a 200 day moving average price of $2.40. The company has a market cap of $479.37 million, a P/E ratio of -10.58 and a beta of 0.24. Ovid Therapeutics has a 12 month low of $1.18 and a 12 month high of $3.11.
Ovid Therapeutics (NASDAQ:OVID – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Sell-side analysts predict that Ovid Therapeutics will post -0.39 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of OVID. Jupiter Topco LLC acquired a new stake in shares of Ovid Therapeutics during the second quarter worth about $55,898,000. BlackRock Inc. purchased a new stake in shares of Ovid Therapeutics in the 2nd quarter valued at about $29,115,000. Janus Henderson Group PLC purchased a new stake in shares of Ovid Therapeutics in the 1st quarter valued at about $23,732,000. Affinity Asset Advisors LLC lifted its holdings in shares of Ovid Therapeutics by 48.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 10,636,318 shares of the company’s stock valued at $23,613,000 after purchasing an additional 3,486,318 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Ovid Therapeutics in the 2nd quarter valued at about $19,953,000. 72.24% of the stock is owned by hedge funds and other institutional investors.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.
Further Reading
- Five stocks we like better than Ovid Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
